Technical Analysis for LIPO - Lipella Pharmaceuticals Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Hammer Candlestick | Bullish | 0.57% | |
| Down 3 Days in a Row | Weakness | 0.57% | |
| Lower Bollinger Band Touch | Weakness | 0.57% | |
| Narrow Range Bar | Range Contraction | -4.68% | |
| NR7 | Range Contraction | -5.72% | |
| Narrow Range Bar | Range Contraction | -5.72% | |
| MACD Bearish Centerline Cross | Bearish | -6.89% |
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| Possible Inside Day | 1 day ago |
| Down 1% | 1 day ago |
| Up 1% | 1 day ago |
| Down 5% | 2 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. We believe that this strategy combines many of the cost efficiencies and risk abatements derived from using existing generic drugs with potential patent protections for our proprietary formulations; this strategy allows us to expedite, protect, and monetize our product candidates. Additionally, we maintain a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists, believing that this focus can potentially help reduce the cost, time and risk associated with obtaining marketing approval.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Drug Therapy Generic Drug
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Drug Therapy Generic Drug
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.5 |
| 52 Week Low | 0.3234 |
| Average Volume | 1,256,189 |
| 200-Day Moving Average | 0.64 |
| 50-Day Moving Average | 0.43 |
| 20-Day Moving Average | 0.43 |
| 10-Day Moving Average | 0.43 |
| Average True Range | 0.04 |
| RSI (14) | 41.18 |
| ADX | 17.62 |
| +DI | 14.02 |
| -DI | 22.88 |
| Chandelier Exit (Long, 3 ATRs) | 0.38 |
| Chandelier Exit (Short, 3 ATRs) | 0.48 |
| Upper Bollinger Bands | 0.49 |
| Lower Bollinger Band | 0.37 |
| Percent B (%b) | 0.19 |
| BandWidth | 28.87 |
| MACD Line | -0.01 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0062 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.42 | ||||
| Resistance 3 (R3) | 0.42 | 0.41 | 0.41 | ||
| Resistance 2 (R2) | 0.41 | 0.40 | 0.41 | 0.41 | |
| Resistance 1 (R1) | 0.40 | 0.40 | 0.39 | 0.40 | 0.41 |
| Pivot Point | 0.39 | 0.39 | 0.39 | 0.39 | 0.39 |
| Support 1 (S1) | 0.38 | 0.38 | 0.38 | 0.38 | 0.37 |
| Support 2 (S2) | 0.37 | 0.38 | 0.37 | 0.37 | |
| Support 3 (S3) | 0.36 | 0.37 | 0.37 | ||
| Support 4 (S4) | 0.36 |
